NEW YORK (GenomeWeb News) – Epigenomics today said that it a French supplementary insurance provider will provide coverage for the firm's Septin9 test for early detection of colorectal cancer.

The Berlin, Germany-based molecular diagnostics firm said that Mutuelle d’Assurance du Corps de Santé Français (MACSF) will reimburse €50 ($68.80) for the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.